OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

by Paul | 17th July 2025 | News

London and New York, NY, July 17, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe...

Recent Posts

  • OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
  • OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
  • OKYO Pharma Announces Purchase of Shares by Director
  • OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
  • OKYO Pharma Announces Purchase of Shares by Chairman

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023